Igor Zydlewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Igor Zydlewski has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Martyna Mrozek
Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
15 shared publications - Martyna Pacanowska-Trawnicka
Independent Public Healthcare Institution of the Ministry of the Interior and Administration, Cracow, Poland
15 shared publications - Małgorzata Blecharczyk
Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
15 shared publications - Agnieszka Zielińska
National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warsaw, Poland
8 shared publications - Aleksandra Jakimowicz
Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland
8 shared publications - Aleksandra Malcher
Nicolaus Copernicus Hospital in Gdańsk, Nowe Ogrody 1-6, 80-803, Gdańsk, Poland
8 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
THERAPEUTIC MANAGEMENT OF VEXAS SYNDROME: A PRACTICAL REVIEW OF CLINICAL MANIFESTATIONS, COMPLICATIONS AND TREATMENT STRATEGIES
Aim: To summarize current clinical knowledge on the manifestations, organ-specific complications, and medical management of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome). Methods: A review of peer-reviewed clinical cohorts, registry evaluations and consensus reports published between 2020 and 2026 was conducted using PubMed, MEDLINE, and Google Scholar. Studies addressing clinical phenotypes, organ manifestations, and treatment responses were analyzed. Results: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in the UBA1 gene within hematopoietic stem cells. It predominantly affects older males and is characterized by systemic inflammation alongside progressive hematologic abnormalities. High-dose oral glucocorticoids reliably achieve rapid flare control - however, steroid dependency is nearly universal and long-term toxicity is substantial. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) show minimal efficacy. Janus kinase (JAK) inhibitors have emerged as the most consistent targeted medical therapy for controlling inflammatory symptoms and reducing steroid exposure. Interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors provide partial benefit but carry risks of secondary loss of response, severe injection-site reactions, or serious infections. For patients with high-risk myelodysplastic syndrome (MDS) features or severe cytopenias, the hypomethylating agent azacitidine reduces clonal burden and improves blood counts. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for eligible candidates. Long-term therapeutic anticoagulation is indicated for unprovoked thrombosis, and routine antimicrobial prophylaxis is essential. Conclusion: Managing VEXAS syndrome requires an integrated strategy: rapid suppression of acute inflammation with corticosteroids, maintenance with targeted therapy (ruxolitinib), clonal suppression (azacitidine or allo-HSCT) for marrow failure and aggressive infection prophylaxis.
- 28 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(51))
Open AccessTHERAPEUTIC MANAGEMENT OF VEXAS SYNDROME: A PRACTICAL REVIEW OF CLINICAL MANIFESTATIONS, COMPLICATIONS AND TREATMENT STRATEGIES
Aim: To summarize current clinical knowledge on the manifestations, organ-specific complications, and medical management of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome). Methods: A review of peer-reviewed clinical cohorts, registry evaluations and consensus reports published between 2020 and 2026 was conducted using PubMed, MEDLINE, and Google Scholar. Studies addressing clinical phenotypes, organ manifestations, and treatment responses were analyzed. Results: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in the UBA1 gene within hematopoietic stem cells. It predominantly affects older males and is characterized by systemic inflammation alongside progressive hematologic abnormalities. High-dose oral glucocorticoids reliably achieve rapid flare control - however, steroid dependency is nearly universal and long-term toxicity is substantial. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) show minimal efficacy. Janus kinase (JAK) inhibitors have emerged as the most consistent targeted medical therapy for controlling inflammatory symptoms and reducing steroid exposure. Interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors provide partial benefit but carry risks of secondary loss of response, severe injection-site reactions, or serious infections. For patients with high-risk myelodysplastic syndrome (MDS) features or severe cytopenias, the hypomethylating agent azacitidine reduces clonal burden and improves blood counts. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for eligible candidates. Long-term therapeutic anticoagulation is indicated for unprovoked thrombosis, and routine antimicrobial prophylaxis is essential. Conclusion: Managing VEXAS syndrome requires an integrated strategy: rapid suppression of acute inflammation with corticosteroids, maintenance with targeted therapy (ruxolitinib), clonal suppression (azacitidine or allo-HSCT) for marrow failure and aggressive infection prophylaxis.
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
SPLENIC ARTERY EMBOLIZATION IN THE MANAGEMENT OF COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Aim: The aim of this study is to present the role of splenic artery embolization (SAE) in the management of selected complications following orthotopic liver transplantation (OLTx), with particular emphasis on its clinical application. Methods: A narrative literature review was conducted, including studies on post-OLTx complications and the use of interventional radiology techniques. Publications addressing the mechanisms underlying these complications and their management using SAE were analyzed. Results: SAE is a minimally invasive endovascular procedure involving occlusion of blood flow within the splenic artery using embolic materials. It is applied in the treatment of selected complications after OLTx, including splenic artery steal syndrome, refractory ascites, and hypersplenism. By reducing blood flow within the splenic vascular bed, SAE improves arterial graft perfusion, decreases portal inflow, and modulates hemodynamic disturbances. Available data indicate high efficacy of this method in selected clinical settings. Conclusion: SAE is an effective and minimally invasive method for the management of selected complications following OLTx. Its use in clinical practice is expected to increase with the growing role of minimally invasive techniques in post-transplant care.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessSPLENIC ARTERY EMBOLIZATION IN THE MANAGEMENT OF COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION
Aim: The aim of this study is to present the role of splenic artery embolization (SAE) in the management of selected complications following orthotopic liver transplantation (OLTx), with particular emphasis on its clinical application. Methods: A narrative literature review was conducted, including studies on post-OLTx complications and the use of interventional radiology techniques. Publications addressing the mechanisms underlying these complications and their management using SAE were analyzed. Results: SAE is a minimally invasive endovascular procedure involving occlusion of blood flow within the splenic artery using embolic materials. It is applied in the treatment of selected complications after OLTx, including splenic artery steal syndrome, refractory ascites, and hypersplenism. By reducing blood flow within the splenic vascular bed, SAE improves arterial graft perfusion, decreases portal inflow, and modulates hemodynamic disturbances. Available data indicate high efficacy of this method in selected clinical settings. Conclusion: SAE is an effective and minimally invasive method for the management of selected complications following OLTx. Its use in clinical practice is expected to increase with the growing role of minimally invasive techniques in post-transplant care.
- Open Access
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
HEPATIC INVOLVEMENT IN RHEUMATOID ARTHRITIS: CAUSES, COMORBIDITIES, AND CLINICAL IMPLICATIONS
Aim: The aim of the study is to summarize the current knowledge on the causes of liver dysfunction in patients with rheumatoid arthritis (RA), with particular emphasis on viral infections, nonalcoholic fatty liver disease (NAFLD), autoimmune liver diseases, and treatment-related hepatotoxicity. Methods: A review of the literature published between 2015 and 2025 was conducted using PubMed and Google Scholar. Studies on hepatic complications in patients with RA were analyzed. Additional relevant studies were identified through reference screening, and selection was based on titles and abstracts. Results: In RA, liver dysfunction mainly reflects comorbid liver disease and metabolic risk rather than drug toxicity. NAFLD is the most frequent hepatic abnormality in RA, with a prevalence exceeding the general population, strongly associated with obesity, insulin resistance, and inflammatory activity. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain clinically relevant due to their potential to mimic or modify RA manifestations and the risk of reactivation during immunosuppressive therapy. Autoimmune liver diseases occur less frequently, though primary biliary cholangitis (PBC) is reported more often in RA than in the general population. Methotrexate (MTX) most commonly causes transient, reversible enzyme abnormalities. Biological therapies and Janus kinase (JAK) inhibitors have varied liver safety profiles, with HBV reactivation in patients without adequate prophylaxis remaining a key concern. Conclusion: Liver dysfunction in RA reflects coexisting liver disease, chronic inflammation or immunogenetic predisposition. Safe long-term management requires regular liver function assessment, mandatory HBV and HCV screening, and identification of metabolic risk factors to minimize hepatic complications.
- 29 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessHEPATIC INVOLVEMENT IN RHEUMATOID ARTHRITIS: CAUSES, COMORBIDITIES, AND CLINICAL IMPLICATIONS
Aim: The aim of the study is to summarize the current knowledge on the causes of liver dysfunction in patients with rheumatoid arthritis (RA), with particular emphasis on viral infections, nonalcoholic fatty liver disease (NAFLD), autoimmune liver diseases, and treatment-related hepatotoxicity. Methods: A review of the literature published between 2015 and 2025 was conducted using PubMed and Google Scholar. Studies on hepatic complications in patients with RA were analyzed. Additional relevant studies were identified through reference screening, and selection was based on titles and abstracts. Results: In RA, liver dysfunction mainly reflects comorbid liver disease and metabolic risk rather than drug toxicity. NAFLD is the most frequent hepatic abnormality in RA, with a prevalence exceeding the general population, strongly associated with obesity, insulin resistance, and inflammatory activity. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain clinically relevant due to their potential to mimic or modify RA manifestations and the risk of reactivation during immunosuppressive therapy. Autoimmune liver diseases occur less frequently, though primary biliary cholangitis (PBC) is reported more often in RA than in the general population. Methotrexate (MTX) most commonly causes transient, reversible enzyme abnormalities. Biological therapies and Janus kinase (JAK) inhibitors have varied liver safety profiles, with HBV reactivation in patients without adequate prophylaxis remaining a key concern. Conclusion: Liver dysfunction in RA reflects coexisting liver disease, chronic inflammation or immunogenetic predisposition. Safe long-term management requires regular liver function assessment, mandatory HBV and HCV screening, and identification of metabolic risk factors to minimize hepatic complications.
- Open Access
- 27 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 60
Pulmonary Hypertension: Pathogenesis, Diagnosis and Management - Current Concepts and Future Perspectives
Background: Pulmonary hypertension (PH) is a complex and heterogeneous conditioncharacterized by elevated pulmonary arterial pressure, increased pulmonary vascularresistance, and progressive right ventricular failure.Objective: This review aims to summarize current knowledge on the pathogenesis, clinicalpresentation, diagnostic approaches, and treatment of PH, with particular emphasis onpulmonary arterial hypertension (PAH).Methods: A narrative review of the literature was conducted, including recent clinicalstudies, review articles, and current guidelines addressing the pathophysiology, diagnosis, andmanagement of PH.Results: Key mechanisms underlying PH include endothelial dysfunction, vascularremodeling, and dysregulation of the prostacyclin, nitric oxide, and endothelin pathways.Diagnostic strategies are based on non-invasive assessment and right heart catheterization.Current therapies improve exercise capacity and quality of life but do not reverse vascularremodeling.Conclusions: Despite significant advances, PH remains associated with poor prognosis.Future research focusing on molecular mechanisms and novel therapeutic targets may enablemore effective and personalized treatment strategies
- 27 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 60
Open AccessPulmonary Hypertension: Pathogenesis, Diagnosis and Management - Current Concepts and Future Perspectives
Background: Pulmonary hypertension (PH) is a complex and heterogeneous conditioncharacterized by elevated pulmonary arterial pressure, increased pulmonary vascularresistance, and progressive right ventricular failure.Objective: This review aims to summarize current knowledge on the pathogenesis, clinicalpresentation, diagnostic approaches, and treatment of PH, with particular emphasis onpulmonary arterial hypertension (PAH).Methods: A narrative review of the literature was conducted, including recent clinicalstudies, review articles, and current guidelines addressing the pathophysiology, diagnosis, andmanagement of PH.Results: Key mechanisms underlying PH include endothelial dysfunction, vascularremodeling, and dysregulation of the prostacyclin, nitric oxide, and endothelin pathways.Diagnostic strategies are based on non-invasive assessment and right heart catheterization.Current therapies improve exercise capacity and quality of life but do not reverse vascularremodeling.Conclusions: Despite significant advances, PH remains associated with poor prognosis.Future research focusing on molecular mechanisms and novel therapeutic targets may enablemore effective and personalized treatment strategies
- Open Access
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Orforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?
Introduction: Facing the increasing number of people suffering from obesity, overweight and weight-related comorbidities, the development of medications that support weight loss is crucial. The currently available therapies based on glucagon-like peptide receptor 1 agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 RAs allow for weight loss of 8-21% [1]. However, a significant factor reducing treatment adherence is subcutaneous route of administation by injection, as well ass - in the case of oral semaglutide – restrictive dosing requirements: the drug need to be taken at least 30 minutes before the first meal, beverage, or other oral medication in the morning and with no more than 120 ml of plain water [2]. Aim of the study: The purpose of this study is to review the safety and tolerance of orforglipron and to compare it with oral semaglutide based on ACHIEVE-3 clinical trail. Material and Methods: Review and analysis of randomised clinical trials available on PubMed. We excluded phase 1 trials in analysis of patients with obesity without diabetes mellitus and patients with DM2. Notably, main clinical trials focusing on orforglipron were funded or supported by Eli Lilly and Company. Conclusions: Orforglipron is definitely promising as a small-molecule GLP-1 receptor agonist. The therapy is effective in body weight reduction and results in a significant, dose-dependent reduction in HbA1c levels. With significant effect on weight loss, cardiometabolic parameters and improvement in glycemic profile, it can be used in combination with a reduced-calorie diet and increased physical activity in adults, as a weight-loss therapy or in patient with type 2 diabetes. However, all of the studies published so far on the innovative molecule of orforglipron were based on limited number of patients, therefore long-term safety, tolerance in a larger population and general long-term impact of orforglipron on health needs extensive studies.
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Open AccessOrforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?
Introduction: Facing the increasing number of people suffering from obesity, overweight and weight-related comorbidities, the development of medications that support weight loss is crucial. The currently available therapies based on glucagon-like peptide receptor 1 agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 RAs allow for weight loss of 8-21% [1]. However, a significant factor reducing treatment adherence is subcutaneous route of administation by injection, as well ass - in the case of oral semaglutide – restrictive dosing requirements: the drug need to be taken at least 30 minutes before the first meal, beverage, or other oral medication in the morning and with no more than 120 ml of plain water [2]. Aim of the study: The purpose of this study is to review the safety and tolerance of orforglipron and to compare it with oral semaglutide based on ACHIEVE-3 clinical trail. Material and Methods: Review and analysis of randomised clinical trials available on PubMed. We excluded phase 1 trials in analysis of patients with obesity without diabetes mellitus and patients with DM2. Notably, main clinical trials focusing on orforglipron were funded or supported by Eli Lilly and Company. Conclusions: Orforglipron is definitely promising as a small-molecule GLP-1 receptor agonist. The therapy is effective in body weight reduction and results in a significant, dose-dependent reduction in HbA1c levels. With significant effect on weight loss, cardiometabolic parameters and improvement in glycemic profile, it can be used in combination with a reduced-calorie diet and increased physical activity in adults, as a weight-loss therapy or in patient with type 2 diabetes. However, all of the studies published so far on the innovative molecule of orforglipron were based on limited number of patients, therefore long-term safety, tolerance in a larger population and general long-term impact of orforglipron on health needs extensive studies.
- Open Access
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Effects of Female Reproductive Hormones on Performance, Injury Risk, and Recovery: Implications for Evidence-Based Practice
Background. Women's participation in sport has grown substantially, yet female athletes remain underrepresented in sport science research, with much of the existing evidence derived from male populations. Fluctuations of estrogen and progesterone across the menstrual cycle, together with widespread use of hormonal contraceptives, are increasingly recognised as factors that may influence athletic outcomes. Aim. To synthesise current evidence on the effects of female reproductive hormones on athletic performance, injury risk, and recovery, and to translate it into practical, individualised recommendations for coaches, practitioners, and athletes. Methods. PubMed was searched for systematic reviews, meta-analyses, and original studies on the menstrual cycle, hormonal contraceptives, and athletic outcomes. Results. Group-level effects of menstrual cycle phase on objective performance outcomes such as strength, power, and endurance are generally small and inconsistent. Evidence linking cycle phase to anterior cruciate ligament injury risk is suggestive but limited by methodological heterogeneity, whereas hormonal contraceptive use does not appear to be protective against musculoskeletal injuries. Outcomes related to recovery appear more sensitive to hormonal context than objective performance measures, with recent evidence converging on menstrual symptom burden as a predictor of disturbed recovery in female athletes. Conclusions. Female reproductive hormones influence multiple physiological systems relevant to sport, but their effects on athletic outcomes are predominantly individual rather than uniform. The strongest evidence-based approach for supporting female athletes combines individualised, symptom-led monitoring with established principles of training periodisation, injury prevention, and athlete education. Progress in this field will depend on longitudinal research with biochemical phase verification and a focus on individual response patterns.
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Open AccessEffects of Female Reproductive Hormones on Performance, Injury Risk, and Recovery: Implications for Evidence-Based Practice
Background. Women's participation in sport has grown substantially, yet female athletes remain underrepresented in sport science research, with much of the existing evidence derived from male populations. Fluctuations of estrogen and progesterone across the menstrual cycle, together with widespread use of hormonal contraceptives, are increasingly recognised as factors that may influence athletic outcomes. Aim. To synthesise current evidence on the effects of female reproductive hormones on athletic performance, injury risk, and recovery, and to translate it into practical, individualised recommendations for coaches, practitioners, and athletes. Methods. PubMed was searched for systematic reviews, meta-analyses, and original studies on the menstrual cycle, hormonal contraceptives, and athletic outcomes. Results. Group-level effects of menstrual cycle phase on objective performance outcomes such as strength, power, and endurance are generally small and inconsistent. Evidence linking cycle phase to anterior cruciate ligament injury risk is suggestive but limited by methodological heterogeneity, whereas hormonal contraceptive use does not appear to be protective against musculoskeletal injuries. Outcomes related to recovery appear more sensitive to hormonal context than objective performance measures, with recent evidence converging on menstrual symptom burden as a predictor of disturbed recovery in female athletes. Conclusions. Female reproductive hormones influence multiple physiological systems relevant to sport, but their effects on athletic outcomes are predominantly individual rather than uniform. The strongest evidence-based approach for supporting female athletes combines individualised, symptom-led monitoring with established principles of training periodisation, injury prevention, and athlete education. Progress in this field will depend on longitudinal research with biochemical phase verification and a focus on individual response patterns.
- Open Access
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Comparison of effectiveness and safety of TAVI and SAVR in treatment of severe, symptomatic aortic stenosis – a literature review
Introduction Aortic stenosis is the most common acquired, valvular heart disease among adults in developed countries. It causes exercise tolerance deterioration, left ventricle hypertrophy and leads to heart failure or even death. Available treatment methods for severe, symptomatic aortic stenosis include Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (SAVR). While it has been proven that TAVI is superior to SAVR in patients with high surgical risk, there is still little data considering patients with lower risk profile. Aim of study The aim of this study is to assess the differences between TAVI procedure and the Surgical Aortic Valve Replacement in terms of their efficacy and safety in patients with severe aortic stenosis and low to intermediate surgical risk. This article is based on the analysis of randomised controlled trials published between years 2021 and 2026. Conclusion TAVI is a safe and effective alternative to SAVR in patients with severe, symptomatic aortic stenosis and low to intermediate surgical risk. It is associated with a lower incidence of major bleeding, stroke and myocardial infarction while presenting comparable or lower mortality in short to medium term. It is, however, correlated with more frequent vascular complications and pacemaker implantations. There is a need for further research on a larger group of patients, with a longer follow-up time in order to assess optimal guidelines for TAVI and SAVR in patients with this risk profile.
- 30 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 56
Open AccessComparison of effectiveness and safety of TAVI and SAVR in treatment of severe, symptomatic aortic stenosis – a literature review
Introduction Aortic stenosis is the most common acquired, valvular heart disease among adults in developed countries. It causes exercise tolerance deterioration, left ventricle hypertrophy and leads to heart failure or even death. Available treatment methods for severe, symptomatic aortic stenosis include Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (SAVR). While it has been proven that TAVI is superior to SAVR in patients with high surgical risk, there is still little data considering patients with lower risk profile. Aim of study The aim of this study is to assess the differences between TAVI procedure and the Surgical Aortic Valve Replacement in terms of their efficacy and safety in patients with severe aortic stenosis and low to intermediate surgical risk. This article is based on the analysis of randomised controlled trials published between years 2021 and 2026. Conclusion TAVI is a safe and effective alternative to SAVR in patients with severe, symptomatic aortic stenosis and low to intermediate surgical risk. It is associated with a lower incidence of major bleeding, stroke and myocardial infarction while presenting comparable or lower mortality in short to medium term. It is, however, correlated with more frequent vascular complications and pacemaker implantations. There is a need for further research on a larger group of patients, with a longer follow-up time in order to assess optimal guidelines for TAVI and SAVR in patients with this risk profile.
- Open Access
- 16 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 55
Maternal and Environmental Risk Factors for Congenital Heart Diseases in Offspring: A Review Article
Background. Congenital heart diseases (CHDs) are the most common congenital anomalies and a leading cause of infant morbidity and mortality. Although genetic factors play an important role, many cases remain unexplained, highlighting the contribution of maternal and environmental exposures. Aim. This review aims to provide a comprehensive and up-to-date synthesis of non-genetic maternal risk factors associated with CHDs in offspring. Material and methods. A literature review was conducted using PubMed, NCBI and Google Scholar, including studies published between 2010 and 2025. Systematic reviews, meta-analyses, cohort and case-control studies evaluating maternal and environmental exposures were analyzed. Results. Evidence indicates that maternal diabetes and obesity are key risk factors, with clear dose-response relationships. Additional contributors include smoking (active and passive), alcohol consumption, infections, fever, psychological stress and environmental pollutants. Protective effects of folic acid and multivitamin supplementation were also observed. Interaction effects between environmental exposures and parental behaviors further increase CHD risk. Conclusions. CHD etiology is multifactorial, involving modifiable maternal and environmental factors. Identification and reduction of these exposures, particularly during early pregnancy, are essential for prevention. Further prospective and mechanistic studies are needed to clarify causal pathways and improve risk reduction strategies.
- 16 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 55
Open AccessMaternal and Environmental Risk Factors for Congenital Heart Diseases in Offspring: A Review Article
Background. Congenital heart diseases (CHDs) are the most common congenital anomalies and a leading cause of infant morbidity and mortality. Although genetic factors play an important role, many cases remain unexplained, highlighting the contribution of maternal and environmental exposures. Aim. This review aims to provide a comprehensive and up-to-date synthesis of non-genetic maternal risk factors associated with CHDs in offspring. Material and methods. A literature review was conducted using PubMed, NCBI and Google Scholar, including studies published between 2010 and 2025. Systematic reviews, meta-analyses, cohort and case-control studies evaluating maternal and environmental exposures were analyzed. Results. Evidence indicates that maternal diabetes and obesity are key risk factors, with clear dose-response relationships. Additional contributors include smoking (active and passive), alcohol consumption, infections, fever, psychological stress and environmental pollutants. Protective effects of folic acid and multivitamin supplementation were also observed. Interaction effects between environmental exposures and parental behaviors further increase CHD risk. Conclusions. CHD etiology is multifactorial, involving modifiable maternal and environmental factors. Identification and reduction of these exposures, particularly during early pregnancy, are essential for prevention. Further prospective and mechanistic studies are needed to clarify causal pathways and improve risk reduction strategies.
- Open Access
- 10 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 55
Probiotics in Pediatric Atopic Dermatitis: Prevention and Therapeutic Potential – A Literature Review
Introduction. Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterised by impaired epidermal barrier and immune dysregulation. It is becoming increasingly prevalent in the pediatric population. Recent research highlights the role of the gut-skin axis and suggests that the intestinal microbiota may influence the development and course of inflammatory skin diseases, including AD. Aim of the study. This review aims to evaluate the current evidence regarding the use of probiotics in the treatment and prevention of atopic dermatitis in the pediatric population. Material and methods. A literature search was conducted using the PubMed database to identify relevant studies discussing the role of probiotics in treatment and prevention of atopic dermatitis in children. Meta-analyses, randomized controlled trials and systematic reviews were included. Results. Included studies suggest that probiotic supplementation may reduce the severity of atopic dermatitis, as measured by the SCORAD index, particularly in moderate-to-severe AD, and when administered for longer durations. Moreover, they may be useful in prevention of AD in high-risk infants, especially during the prenatal period. However, results vary depending on study design, probiotic strain, population and duration of supplementation. Conclusion. Probiotics may be a promising new strategy as an adjunct therapy in the treatment and prevention of pediatric atopic dermatitis. Nevertheless, further research, mostly well-designed randomized controlled trials are needed in order to determine optimal strains, dosage and duration of treatment.
- 10 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 55
Open AccessProbiotics in Pediatric Atopic Dermatitis: Prevention and Therapeutic Potential – A Literature Review
Introduction. Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterised by impaired epidermal barrier and immune dysregulation. It is becoming increasingly prevalent in the pediatric population. Recent research highlights the role of the gut-skin axis and suggests that the intestinal microbiota may influence the development and course of inflammatory skin diseases, including AD. Aim of the study. This review aims to evaluate the current evidence regarding the use of probiotics in the treatment and prevention of atopic dermatitis in the pediatric population. Material and methods. A literature search was conducted using the PubMed database to identify relevant studies discussing the role of probiotics in treatment and prevention of atopic dermatitis in children. Meta-analyses, randomized controlled trials and systematic reviews were included. Results. Included studies suggest that probiotic supplementation may reduce the severity of atopic dermatitis, as measured by the SCORAD index, particularly in moderate-to-severe AD, and when administered for longer durations. Moreover, they may be useful in prevention of AD in high-risk infants, especially during the prenatal period. However, results vary depending on study design, probiotic strain, population and duration of supplementation. Conclusion. Probiotics may be a promising new strategy as an adjunct therapy in the treatment and prevention of pediatric atopic dermatitis. Nevertheless, further research, mostly well-designed randomized controlled trials are needed in order to determine optimal strains, dosage and duration of treatment.
- Open Access
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
From Balance to Rupture: Vaginal Microbiome in pPROM
PROM and its preterm form, pPROM, are major contributors to preterm birth and remain closely associated with serious maternal and neonatal complications. Growing evidence suggests that disruption of vaginal microbial homeostasis mayis closely linked to the pathogenesis of pPROM. In particular, the loss of protective Lactobacillus crispatus, accompanied by a shift toward Lactobacillus iners, anaerobic bacteria, and increased microbial diversity, appears to destabilize the vaginal ecosystem, promote local inflammation, activate matrix metalloproteinases, and ultimately compromise the structural integrity of the fetal membranes. Current empirical antibiotic therapy for pPROM does not account for interindividual variability in the vaginal microbiota and may paradoxically aggravate dysbiosis. In response to these limitations, emerging therapeutic strategies are increasingly focused on microbiota-targeted interventions, including personalized probiotic therapies, immunological and biological approaches, and vaginal microbiota transplantation. In addition, specific microbial signatures may serve as potential biomarkers of pPROM, thereby opening new avenues for personalized prevention and treatment. Although further prospective studies are required to validate the safety and efficacy of these emerging therapies, their potential already represents a promising direction for the future of modern perinatal medicine.
- 7 May 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 91
Open AccessFrom Balance to Rupture: Vaginal Microbiome in pPROM
PROM and its preterm form, pPROM, are major contributors to preterm birth and remain closely associated with serious maternal and neonatal complications. Growing evidence suggests that disruption of vaginal microbial homeostasis mayis closely linked to the pathogenesis of pPROM. In particular, the loss of protective Lactobacillus crispatus, accompanied by a shift toward Lactobacillus iners, anaerobic bacteria, and increased microbial diversity, appears to destabilize the vaginal ecosystem, promote local inflammation, activate matrix metalloproteinases, and ultimately compromise the structural integrity of the fetal membranes. Current empirical antibiotic therapy for pPROM does not account for interindividual variability in the vaginal microbiota and may paradoxically aggravate dysbiosis. In response to these limitations, emerging therapeutic strategies are increasingly focused on microbiota-targeted interventions, including personalized probiotic therapies, immunological and biological approaches, and vaginal microbiota transplantation. In addition, specific microbial signatures may serve as potential biomarkers of pPROM, thereby opening new avenues for personalized prevention and treatment. Although further prospective studies are required to validate the safety and efficacy of these emerging therapies, their potential already represents a promising direction for the future of modern perinatal medicine.